The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Charles CraddockDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, How might the MORPHO trial of gilteritinib impact clinical practice?
How might the MORPHO trial of gilteritinib impact clinical practice?
Firstly, Craddock provides an overview of the phase III MORPHO trial (NCT02997202), highlighting the impact of measurable residual disease status pre- or posttransplant on survival outcomes; then, he considers the implications on future trials assessing posttransplant maintenance therapies in other patient subgroups. Craddock concludes by emphasizing the need for more randomized trials to optimize transplant outcomes.
This interview can also be accessed as a podcast here.
